… This systematic review synthesized 90 studies with direct comparisons of two or three EGFR
TKIs, the majority of which comparing gefitinib with erlotinib. It was found that gefitinib had …

… according to different lines of gefitinib or erlotinib. The disparities of choices on gefitinib or
erlotinib (more male, non-adenocarcinoma and smokers using erlotinib) were still noted in all …

… Patients who used either gefitinib or erlotinib as second-line therapy were excluded. We
did not plan to analyse gefitinib or erlotinib as second-line therapy because erlotinib gained …

… The erlotinib group also showed more of a tendency to … ; our data suggest that gefitinib and
erlotinib might have almost … , although erlotinib appears to have higher toxicity than gefitinib …

… We have preliminary results of phase III clinical studies comparing … -1 clinical trial) and
erlotinib or gefitinib in first-line treatment of … studies comparing gefitinib, erlotinib, and afatinib. …

… Cancer trial comparing gefitinib with placebo in patients with advanced NSCLC who had
failed prior chemotherapy did not show any significant improvement of survival with gefitinib in …

… The adequate-powered, direct comparisons of gefitinib against erlotinib under the same
clinical scenarios are lacking. There is no evidence at present that the efficacy of these two …

… MST compared with gefitinib and icotinib (P<0.05). In conclusion, gefitinib, erlotinib and
icotinib … However, gefitinib resulted in a lower frequency of fatigue, and nausea and vomiting, …

… Comparison of effectiveness (PFS) of erlotinib and gefitinib: The PFS for each drug was
estimated from the number of days without disease progression and was compared (Figure). …

… three available EGFR TKIs (gefitinib, erlotinib, and afatinib) for the … However, whether gefitinib,
erlotinib, or afatinib is most … to compare the effectiveness of gefitinib, erlotinib, and afatinib. …